XOMA Royalty (NASDAQ:XOMA) Hits New 12-Month High – Should You Buy?

Shares of XOMA Royalty Corporation (NASDAQ:XOMA) reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $43.00 and last traded at $42.9850, with a volume of 71958 shares trading hands. The stock had previously closed at $42.62.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on XOMA shares. HC Wainwright lowered shares of XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 price objective for the company. in a research note on Thursday, April 30th. Weiss Ratings upgraded XOMA Royalty from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, May 29th. Zacks Research raised XOMA Royalty from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 8th. Benchmark downgraded XOMA Royalty from a “buy” rating to a “hold” rating in a report on Friday, May 22nd. Finally, Lucid Cap Mkts lowered XOMA Royalty from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 27th. One investment analyst has rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, XOMA Royalty has a consensus rating of “Hold” and a consensus target price of $53.75.

XOMA Royalty Trading Up 0.9%

The stock has a market cap of $539.22 million, a price-to-earnings ratio of 27.39 and a beta of 0.86. The company has a quick ratio of 3.59, a current ratio of 3.59 and a debt-to-equity ratio of 0.96. The business has a 50-day moving average of $41.55 and a 200-day moving average of $32.81.

XOMA Royalty (NASDAQ:XOMA) last issued its earnings results on Tuesday, May 12th. The biotechnology company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.02). XOMA Royalty had a net margin of 53.46% and a return on equity of 12.56%. The firm had revenue of $12.32 million during the quarter, compared to analysts’ expectations of $13.91 million. As a group, research analysts forecast that XOMA Royalty Corporation will post 0.9 earnings per share for the current year.

Hedge Funds Weigh In On XOMA Royalty

A number of hedge funds have recently added to or reduced their stakes in XOMA. JPMorgan Chase & Co. lifted its stake in XOMA Royalty by 13.9% in the second quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 543 shares during the last quarter. Russell Investments Group Ltd. increased its stake in shares of XOMA Royalty by 3,436.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 756 shares during the last quarter. State of Alaska Department of Revenue bought a new position in shares of XOMA Royalty during the 4th quarter valued at $27,000. Dimensional Fund Advisors LP lifted its stake in shares of XOMA Royalty by 4.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 29,190 shares of the biotechnology company’s stock valued at $1,124,000 after purchasing an additional 1,269 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in shares of XOMA Royalty by 203.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,523 shares during the last quarter. Institutional investors and hedge funds own 95.92% of the company’s stock.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.